2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Epidiolex - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:		Prescriber Name:	
Member Number:		Fax: Phone:	
Date of Birth:		Office Contact:	
Line of Business: Medicare		NPI: State Lic ID:	
Address:		Address:	
City, State ZIP:		City, State ZIP:	
Primary Phone:		Specialty/facility name (if applicable):	
•	<u>DITED REVIEW</u> : By checking this box and signing belin in the enrollee's ability to regain maximum for the enrollee of	ow, I certify that applying the 72 hour standard review timeframe may seriously jeopardize function.	
Drug Name:			
Strength:			
Directions / SIG:			
Please attach any pertinent medical history including labs and information for this member that may support approval. Please answer the following questions and sign.			
Q1. Does the product?	patient have a hypersensitivity	to cannabidiol or any of the ingredients in the	
☐ Yes		□ No	
Q2. Does the patient have a documented diagnosis of Dravet syndrome (DS) or Lennox-Gastaut syndrome (LGS) or Tuberous Sclerosis Complex (TSC)?			
☐ Yes		□ No	
Q3. Is Epidiolex being prescribed by a neurologist or an epileptologist?			
☐ Yes		□ No	
Q4. Is the par	tient 1 year of age or older?		
☐ Yes		□ No	
		serum transaminases (ALT and AST) and total itored periodically during therapy?	
☐Yes		□ No	
	patient failed to become seizure- ument names of antiepileptic dru	free with adequate trials of at least 2 antiepileptic gs tried, dates and duration.)	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

2024 MEDICARE PRIOR AUTHORIZATION REQUEST FORM



Epidiolex - Medicare

Phone: 215-991-4300 Fax back to: 866-371-3239

Jefferson Health Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL delay the review process.

Patient Name:	Prescriber Name:		
□Yes	□ No		
Q7. Will Epidiolex be used as adjunctive therapy with other antiepileptic drug(s) (provide name of drug or drugs)?			
□Yes	□ No		
Q8. Is the requested Epidiolex dose in accordance with FDA-approved labeled dose not exceeding 20 mg/kg/day for treatment of seizures associated with Lennox-Gastaut Syndrome and Dravet Syndrome or dose not exceeding 25 mg/kg/day for treatment of seizures associated with Tuberous Sclerosis Complex?			
□Yes	□ No		
Q9. Requested Duration:			
☐ 12 Months	☐ Other:		
Q10. Additional Information:			
Prescriber Signature	Date		
	2024 Medicare Prior Authorization Request		